Mylan Tries To Escape Pharmacy's EpiPen Antitrust Suit

By Meghan Kelly · December 15, 2020, 5:46 PM EST

Mylan Pharmaceuticals has urged a Kansas federal judge to drop it from a suit alleging it inflated the price for the emergency allergy medication EpiPen, arguing the retail and online pharmacy...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

2:17-md-02785

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

2:20-cv-02065

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020

Featured Stories

What The MAHA Report Tells Us About Its Future Agenda No Photo Available

Yeji Jesse Lee

A long-awaited report from a commission tasked with addressing childhood chronic disease in the United States signals key parts of the... (more story)

The Surgical Pay Gap: How Bias May Hurt Women's Health No Photo Available

Hannah Albarazi

Medical and legal professionals warn that systemic sex discrimination in U.S. surgical valuations — in the form of lower pay for proce... (more story)

1 Year In, Firms Grapple With Scope Of Wash. Health Data Law No Photo Available

Dan McKay

A year after Washington’s landmark health privacy law took effect, attorneys are bracing for the first judicial interpretation definin... (more story)